-
公开(公告)号:US20190022243A1
公开(公告)日:2019-01-24
申请号:US16069395
申请日:2017-01-13
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20220324980A1
公开(公告)日:2022-10-13
申请号:US17695550
申请日:2022-03-15
Applicant: GENMAB A/S
Inventor: Louise KOOPMAN , Patrick ENGELBERTS , Dennis VERZIJL , Edward N. VAN DEN BRINK , Rik RADEMAKER , Sieto BOSGRA , Frederikke L. EGEROD , David SATIJN , Esther C. W BREIJ
Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20230321261A1
公开(公告)日:2023-10-12
申请号:US17957302
申请日:2022-09-30
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61P35/00 , C07K16/2863 , A61K2039/505 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: Antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of melanoma in combination with one or more MAPK pathway inhibitors such as, e.g., a BRAF inhibitor and/or a MEK inhibitor.
-
公开(公告)号:US20210292418A1
公开(公告)日:2021-09-23
申请号:US17204604
申请日:2021-03-17
Applicant: GENMAB A/S
Inventor: Louise KOOPMAN , Patrick ENGELBERTS , Dennis VERZIJL , Edward N. VAN DEN BRINK , Rik RADEMAKER , Sieto BOSGRA , Frederikke L. EGEROD , David SATIJN , Esther C. W. BREIJ
Abstract: The present invention relates to antibodies binding to B7H4, including bispecific antibodies binding to B7H4 and CD3. The invention further provides pharmaceutical compositions comprising the antibodies and use of the antibodies for therapeutic and diagnostic procedures, in particular in cancer therapy.
-
公开(公告)号:US20180326084A1
公开(公告)日:2018-11-15
申请号:US15742818
申请日:2016-07-08
Applicant: GENMAB A/S
Inventor: Julia BOSHUIZEN , Kirstine JACOBSEN , Esther BREIJ , Louise KOOPMAN , David SATIJN , Edward VAN DEN BRINK , Dennis VERZIJL , Rob DE JONG , Riemke VAN DIJKHUIZEN RADERSMA , Daniel PEEPER , Henrik Jørn DITZEL , Paul PARREN
CPC classification number: A61K47/6803 , A61K39/001102 , A61K45/06 , A61K47/6801 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6857 , A61K47/6869 , A61K2039/505 , A61P35/00 , C07K16/2863 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/732 , C07K2317/77 , C07K2317/92
Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) binding to human AXL for therapeutic use, particularly for treatment of resistant or refractory cancers.
-
-
-
-